MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 05-16-2026
DURECT Corporation Cash and Cash Equivalents 2011-2026 | DRRX
Annual Cash and Cash Equivalents DURECT Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11 M | 28.4 M | 43.5 M | 50 M | 21.5 M | 34.9 M | 31.6 M | 29.4 M | 5.4 M | 3.58 M | 2.68 M | 7.84 M | 11.2 M | 8.9 M | 10.4 M | 8.29 M | 29.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 50 M | 2.68 M | 19.9 M |
Quarterly Cash and Cash Equivalents DURECT Corporation
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.5 M | 7.96 M | 9.09 M | 15.8 M | 19.4 M | 39.1 M | 31.9 M | 39.4 M | 43.5 M | 50.5 M | 47.3 M | 49.6 M | 49.8 M | 55.6 M | 56.1 M | 57.5 M | 21.3 M | 21.3 M | 21.3 M | 21.3 M | 34.9 M | 34.9 M | 34.9 M | 34.9 M | 31.6 M | 31.6 M | 31.6 M | 31.6 M | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 5.4 M | 5.4 M | 5.4 M | 5.4 M | 3.58 M | 3.58 M | 3.58 M | 3.58 M | 2.68 M | 2.68 M | 2.68 M | 2.68 M | 7.84 M | 7.84 M | 7.84 M | 7.84 M | 11.2 M | 11.2 M | 11.2 M | 11.2 M | 8.9 M | 8.9 M | 8.9 M | 8.9 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 57.5 M | 2.68 M | 21.5 M |
Cash and Cash Equivalents of other stocks in the Drug manufacturers industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Evoke Pharma
EVOK
|
13.6 M | - | - | $ 36.6 M |  USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
974 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
5.89 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
1.08 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
37.2 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
2.56 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
12.1 M | - | - | $ 142 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
11.4 M | $ 5.47 | -1.08 % | $ 81.3 M | USA |
 |
Cronos Group
CRON
|
792 M | $ 2.74 | 2.43 % | $ 1.05 B |  Canada |
 |
Harrow Health
HROW
|
72.9 M | $ 32.24 | 4.46 % | $ 1.19 B | USA |
 |
Athenex
ATNX
|
30.4 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
51.4 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
289 M | - | - | $ 11.5 B | USA |
 |
HEXO Corp.
HEXO
|
83.2 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Organogenesis Holdings
ORGO
|
93.7 M | $ 2.61 | 2.16 % | $ 331 M | USA |
 |
Pacira BioSciences
PCRX
|
277 M | $ 23.59 | 2.57 % | $ 1.09 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
55.3 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
778 M | - | - | $ 28.9 M |  Irlanda |
 |
Bausch Health Companies
BHC
|
947 M | $ 5.41 | -1.46 % | $ 1.97 B | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
5.37 M | $ 1.05 | -1.87 % | $ 1.3 M | USA |
 |
Canopy Growth Corporation
CGC
|
114 M | $ 1.08 | 4.37 % | $ 116 M | Canada |
 |
Solid Biosciences
SLDB
|
59.9 M | $ 6.54 | 1.08 % | $ 572 M | USA |
 |
Aurora Cannabis
ACB
|
138 M | $ 3.55 | 2.41 % | $ 195 M | Canada |
 |
Jupiter Wellness
JUPW
|
2.28 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
87.9 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
107 M | $ 1.12 | 4.67 % | $ 107 M | Canada |
 |
Tilray
TLRY
|
207 M | $ 5.43 | 0.37 % | $ 3.36 B | Canada |
 |
cbdMD
YCBD
|
2.26 M | $ 0.77 | 4.21 % | $ 3.1 M | USA |
 |
Evolus
EOLS
|
53.8 M | $ 6.49 | -1.59 % | $ 418 M | USA |
 |
Sundial Growers
SNDL
|
252 M | $ 1.47 | 1.74 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
112 M | $ 8.29 | 1.41 % | $ 424 M | USA |
 |
Veru
VERU
|
15.8 M | $ 2.19 | 0.92 % | $ 32.1 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
104 M | - | - | $ 193 M | Canada |
 |
Assertio Holdings
ASRT
|
10.2 M | $ 23.43 | -0.06 % | $ 150 M | USA |
 |
ProPhase Labs
PRPH
|
9.11 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
112 M | - | - | $ 1.42 B | USA |
 |
PetIQ
PETQ
|
116 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
3.5 M | $ 7.28 | 1.53 % | $ 287 M | USA |
 |
Recro Pharma
REPH
|
8.1 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
73.7 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
21.3 M | $ 0.69 | 3.46 % | $ 34.5 M | USA |
 |
PLx Pharma
PLXP
|
69.4 M | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
1.32 B | $ 16.39 | -1.24 % | $ 19.1 B | USA |
 |
Zomedica Corp.
ZOM
|
9.02 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
50.6 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
10.7 M | $ 0.8 | -2.37 % | $ 28.8 M | USA |
 |
Tricida
TCDA
|
21.1 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
345 K | $ 0.7 | -7.02 % | $ 3 M |  China |
 |
TherapeuticsMD
TXMD
|
7.48 M | $ 2.06 | -0.96 % | $ 23.8 M | USA |